hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06345560, orgStudyIdInfo id: 077766, briefTitle: Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Chulalongkorn University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to investigate whether bariatric surgery affects Drospirenone only pills absorption, conditionsModule conditions: Contraception, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Pre-bariatric surgery pharmacokinetics study of Drospirenone compare with post-bariatric surgery, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 16, type: ESTIMATED, armsInterventionsModule interventions name: Drospirenone, outcomesModule primaryOutcomes measure: Plasma concentration versus Time of Drospirenone, secondaryOutcomes measure: Number of Participants With Treatment-Related Adverse Events, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Chulalongkorn University, city: Bangkok, zip: 10330, country: Thailand, contacts name: Punyawee Utaipatanacheep, role: CONTACT, geoPoint lat: 13.75398, lon: 100.50144, hasResults: False
protocolSection identificationModule nctId: NCT06345547, orgStudyIdInfo id: EDGE 003539, briefTitle: Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE), acronym: MMUSCLE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-02, primaryCompletionDateStruct date: 2026-05-02, completionDateStruct date: 2027-05-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University Hospital, Antwerp, class: OTHER, descriptionModule briefSummary: The goal of this observational cohort study is to learn about loss of muscle mass and muscle strength (sarcopenia) in patients with cirrhosis. The main question\[s\] it aims to answer are:* what is the prevalence and development of sarcopenia in cirrhosis?* what is the role of malnutrition? Participants will  * undergo a muscle ultrasound of the lower and upper limb muscles  * handgrip strength will be measured  * malnutrition screening and assessment  * complete a questionnaire to assess quality of life, conditionsModule conditions: Sarcopenia, conditions: Cirrhosis, conditions: Malnutrition, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: ultrasound, outcomesModule primaryOutcomes measure: Prevalence of sarcopenia: muscle mass, primaryOutcomes measure: Prevalence of sarcopenia: muscle strength, primaryOutcomes measure: Development of sarcopenia: changes in muscle mass, primaryOutcomes measure: Development of sarcopenia: changes in muscle strength, primaryOutcomes measure: Development of sarcopenia: changes in muscle quality, secondaryOutcomes measure: Decompensation events: MELD score • MELD evolution, secondaryOutcomes measure: Decompensation events: mortality • MELD evolution, secondaryOutcomes measure: Decompensation events: transplantation • MELD evolution, secondaryOutcomes measure: Malnutrition, secondaryOutcomes measure: Quality of life in cirrhosis, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Antwerp, city: Edegem, state: Antwerpen, zip: 2650, country: Belgium, contacts name: Karolien Dams, MD, role: CONTACT, phone: +3238213635, phoneExt: 5175, email: karolien.dams@uza.be, contacts name: Jolien Derdeyn, MD, role: CONTACT, phone: +328213807, phoneExt: 3807, email: jolien.derdeyn@uza.be, contacts name: Jolien Derdeyn, MD, role: SUB_INVESTIGATOR, contacts name: Thomas Vanwolleghem, MD, Phd, role: SUB_INVESTIGATOR, contacts name: Philippe Jorens, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Stany Perkisas, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Karolien Dams, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 51.15662, lon: 4.44504, hasResults: False
protocolSection identificationModule nctId: NCT06345534, orgStudyIdInfo id: ONZ-2023-0255, briefTitle: FAST-FORWARD vs HAI5, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2033-12-31, completionDateStruct date: 2033-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University Hospital, Ghent, class: OTHER, descriptionModule briefSummary: Randomized comparison between the FAST-FORWARD schedule and the HAI5 schedule for breast cancer radiotherapy in 5 fractions., conditionsModule conditions: Cancer, Breast, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Patients participating in the study will be randomized 1:1 between the FAST-FORWARD schedule and the HAI5 schedule. The first group is treated according to the FAST-FORWARD schedule, consisting of 5 radiation sessions on 5 consecutive working days (e.g. Monday to Friday). 2 rest days are allowed in the schedule, so that the treatment lasts a maximum of 7 days. The second group is treated according to the HAI5 schedule, developed by the radiotherapy department of Ghent University Hospital. In this schedule, at least 1 day of rest is scheduled between each treatment session, so the treatment is administered over 10-14 days., primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: Both healthcare provider and patient know the treatment, enrollmentInfo count: 740, type: ESTIMATED, armsInterventionsModule interventions name: Questionnaire, outcomesModule primaryOutcomes measure: Early side effects, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universitary Hospital, city: Ghent, zip: 9000, country: Belgium, contacts name: Liv Veldeman, MD, PhD, role: CONTACT, phone: 09 332 30 15, email: liv.veldeman@uzgent.be, contacts name: Emma Van Damme, MD, role: CONTACT, phone: 09 332 19 53, email: emma.vandamme@uzgent.be, geoPoint lat: 51.05, lon: 3.71667, hasResults: False
protocolSection identificationModule nctId: NCT06345521, orgStudyIdInfo id: 2022-1-4032-3, briefTitle: The Follow-up System of Pediatric Heart Failure and the Establishment of End-stage Heart Failure Registry, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2024-06-22, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: China National Center for Cardiovascular Diseases, class: OTHER_GOV, collaborators name: Peking University First Hospital, collaborators name: Beijing Children's Hospital, descriptionModule briefSummary: Establish a follow-up management system for pediatric heart failure and a registration platform for end-stage heart failure, conditionsModule conditions: Heart Failure, conditions: Congenital, conditions: End-stage Heart Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: the recurrence rate of heart failure, secondaryOutcomes measure: NT-proBNP level, secondaryOutcomes measure: Incidence rate of drug adverse reactions, secondaryOutcomes measure: Readmission rate for heart failure, eligibilityModule sex: ALL, maximumAge: 14 Years, stdAges: CHILD, contactsLocationsModule locations facility: Fuwai hospital, status: RECRUITING, city: Beijing, country: China, contacts name: Shoujun Li, MD, role: CONTACT, phone: +86 13501071589, email: drlishoujunfw@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06345495, orgStudyIdInfo id: 2023-0899, secondaryIdInfos id: NCI-2024-02814, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-30, primaryCompletionDateStruct date: 2027-01-01, completionDateStruct date: 2029-01-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, collaborators name: Incyte Corporation, descriptionModule briefSummary: To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed., conditionsModule conditions: Splenomegaly, conditions: Myelofibrosis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Ruxolitinib, interventions name: Allogeneic Stem Cell Transplantation, interventions name: Levetiracetam, interventions name: Eltrombopag, interventions name: Busulfan, interventions name: Romiplostim, interventions name: Fludarabine phosphate, interventions name: Cyclophosphamide, interventions name: Mesna, interventions name: Tacrolimus, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06345482, orgStudyIdInfo id: MHB039A-A-101, briefTitle: A Study of MHB039A for Advanced Solid Tumor, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2028-04-01, completionDateStruct date: 2029-06-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Minghui Pharmaceutical (Hangzhou) Ltd, class: INDUSTRY, descriptionModule briefSummary: Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors., conditionsModule conditions: Advanced Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 196, type: ESTIMATED, armsInterventionsModule interventions name: MHB039A, outcomesModule primaryOutcomes measure: Incidence of participants with adverse events (AE), primaryOutcomes measure: Number of participants with dose-limiting toxicity (DLT), secondaryOutcomes measure: Maximum Plasma Concentration (Cmax) of MHB039A, secondaryOutcomes measure: The area under the plasma concentration-time curve (AUC) of MHB039A, secondaryOutcomes measure: To detectable anti-drug antibodies with treated subjects, secondaryOutcomes measure: Objective response rate (ORR), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Chest Hospital, city: Shanghai, state: Shanghai, zip: 200030, country: China, contacts name: Shun Lu, MD, role: CONTACT, phone: 13601813062, email: shun_lu@hotmail.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06345469, orgStudyIdInfo id: O-PBM2, briefTitle: Cost Analysis of Therapies for Severe Anemia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2026-05-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Helios Klinik Gotha/Ohrdruf, class: OTHER, collaborators name: Marisa Eichner, descriptionModule briefSummary: The goal of this observational study is to learn about the costs that occur when participants with severe anemia are treated with blood transfusions or with patient blood management (PBM). PBM means that the body of the participant is stimulated to produce new blood by itself rather than receiving it from a blood donor, and to reduce blood losses.The main question the study aims to answer is: Do participants treated with transfusions incur the same treatment costs than participants treated with PBM? And how much costs are this in relation to the lives saved by the therapy of severe anemia?, conditionsModule conditions: Severe Anemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 640, type: ESTIMATED, armsInterventionsModule interventions name: Patient blood management (PBM), interventions name: Allogeneic transfusion, outcomesModule primaryOutcomes measure: cost-effectiveness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06345456, orgStudyIdInfo id: izmirkatip, briefTitle: The Value of End-tidal Capnography in Gastrointestinal Bleeding, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-06-01, primaryCompletionDateStruct date: 2021-01-01, completionDateStruct date: 2021-01-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Izmir Katip Celebi University, class: OTHER, descriptionModule briefSummary: Gastrointestinal bleeding is a condition that frequently presents to emergency departments and can be fatal if diagnosis and treatment are delayed. The working mechanism of end tidal capnography is simply to detect the respiratory carbon dioxide level.In our study, the investigators aimed to determine the severity of gastrointestinal bleeding by using the Glaskow Blachford Score and AIMS65 score in cases presenting with gastrointestinal bleeding, to determine the end tidal carbon dioxide value by capnography in these cases and to determine its effectiveness in evaluating mortality and morbidity in gastrointestinal bleeding., conditionsModule conditions: Gastro Intestinal Bleeding, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 103, type: ACTUAL, armsInterventionsModule interventions name: End-tidal capnography, outcomesModule primaryOutcomes measure: The correlation between ETCO2 value and mortality in patients with gastrointestinal bleeding will be investigated., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Katip Çelebi Üniversitesi, city: İzmir, country: Turkey, geoPoint lat: 38.41273, lon: 27.13838, documentSection largeDocumentModule largeDocs typeAbbrev: SAP, hasProtocol: False, hasSap: True, hasIcf: False, label: Statistical Analysis Plan, date: 2020-06-01, uploadDate: 2024-04-01T04:48, filename: SAP_000.pdf, size: 281538, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2020-06-01, uploadDate: 2024-04-01T04:35, filename: ICF_001.pdf, size: 418132, hasResults: False
protocolSection identificationModule nctId: NCT06345443, orgStudyIdInfo id: 23-005288, briefTitle: NRM on Vascular Perfusion in Heathy Adults, acronym: NRM, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-05-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults., conditionsModule conditions: Vascular Stiffness, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, maskingDescription: The pharmacy will be responsible for randomization and dispensing appropriate randomized intervention., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Nicotinamide Riboside Malate, interventions name: Placebo, outcomesModule primaryOutcomes measure: Reduction of Endothelial stiffness, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Snigdha Panda, BS, role: CONTACT, phone: 507-538-5827, email: GIMRESEARCHSTUDIES@mayo.edu, contacts name: Jennifer Soderlind, role: CONTACT, phone: 507-284-4799, email: GIMRESEARCHSTUDIES@mayo.edu, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06345430, orgStudyIdInfo id: 2023-14, briefTitle: Wearable Technological Device Applied to Patients With Chronic Pain, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-11-18, primaryCompletionDateStruct date: 2024-01-15, completionDateStruct date: 2024-01-30, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Hacettepe University, class: OTHER, descriptionModule briefSummary: Within the scope of this research, a single session of Wearable Technological Device (Exopulse Molli-Suit) will be applied to patients with chronic back and neck pain. The results will be evaluated acutely, after 24 hours, after 1 week and after 1 month., conditionsModule conditions: Neck Pain, conditions: Low Back Pain, conditions: Chronic Pain, conditions: Musculoskeletal Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: Exopulse Molli-Suit (Wearable Technological Device), outcomesModule primaryOutcomes measure: Pain Severity, secondaryOutcomes measure: Sleep Qaulity, secondaryOutcomes measure: Disability Level, secondaryOutcomes measure: Repetitive Reach Test, secondaryOutcomes measure: Body Composition Analysis, secondaryOutcomes measure: Lifting object overhead test, secondaryOutcomes measure: Sustained Overhead Work Test, secondaryOutcomes measure: back performance test, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Yasemin Özel Aslıyüce, city: Yeni̇mahalle, state: Ankara, zip: 06100, country: Turkey, hasResults: False
protocolSection identificationModule nctId: NCT06345404, orgStudyIdInfo id: CPI-818-003, briefTitle: Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Corvus Pharmaceuticals, Inc., class: INDUSTRY, descriptionModule briefSummary: Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD, conditionsModule conditions: Atopic Dermatitis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: Sequential Dose Escalation, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Blinded Placebo-Controlled, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Soquelitinib, interventions name: Placebo, outcomesModule primaryOutcomes measure: Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiograms, secondaryOutcomes measure: To determine the efficacy of soquelitinib in participants with atopic dermatitis as measured by percent change in Eczema and Severity Index (EASI), secondaryOutcomes measure: To determine the efficacy of soquelitinib in participants with atopic dermatitis as measured by change in percent reaching validated Investigator Global Assessment (vIGA) of 0 or 1, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Corvus Clinical Trials Information, status: RECRUITING, city: Burlingame, state: California, zip: 94010, country: United States, contacts name: Liza Tom, role: CONTACT, phone: 650-900-4514, email: ltom@corvuspharma.com, contacts name: Gabriel Luciano, role: CONTACT, phone: 6509004548, email: gluciano@corvuspharma.com, geoPoint lat: 37.5841, lon: -122.36608, hasResults: False
protocolSection identificationModule nctId: NCT06345391, orgStudyIdInfo id: PANACEA_CO-CREATION_2024, briefTitle: Co-creation of Pain Science Education for Children Living Beyond Cancer, acronym: PANACEA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Vrije Universiteit Brussel, class: OTHER, collaborators name: Universitair Ziekenhuis Brussel, collaborators name: University Ghent, collaborators name: University Hospital, Ghent, collaborators name: University of Calgary, descriptionModule briefSummary: A pain science education (PSE) intervention for children (8-12y) living beyond cancer (CBC) will be developed through a co-creational approach with CBC, their parents and pediatric oncology clinicians. The study will be guided by the Intervention Mapping Protocol., conditionsModule conditions: Children Living Beyond Cancer (i.e. Child Cancer Survivor), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Co-creation, interventions name: Concept Mapping, outcomesModule primaryOutcomes measure: Satisfaction with the co-created intervention, secondaryOutcomes measure: Understandability of the co-created intervention, secondaryOutcomes measure: Empowerment with regard to the co-created intervention, secondaryOutcomes measure: Ownership of the intervention development, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Vrije Universiteit Brussel, city: Jette, state: Brussels, zip: 1090, country: Belgium, contacts name: Emma Rheel, PhD, role: CONTACT, phone: +32496908353, email: emma.rheel@vub.be, contacts name: Kelly Ickmans, PhD, role: CONTACT, phone: +32498483347, email: kelly.ickmans@vub.be, contacts name: Sophie Pleysier, MSc, role: SUB_INVESTIGATOR, geoPoint lat: 50.87309, lon: 4.33419, hasResults: False